TSX open
Loading markets…

Advertisement

Stocks

Knight Therapeutics Inc. GUD Earnings Miss Estimates by 188.0%

By Wealth Awesome -

Follow live quotes and coverage.

Stocks & ETFs:GUD.TO

Get GUD alerts:

Photos provided by Pexels

Knight Therapeutics faces a significant earnings miss, raising questions about future performance.

Recent earnings trend

Advertisement

Knight Therapeutics Inc.

GUD.TO

Full stock page →

GUD.TO

Knight Therapeutics Inc.

Source:WealthAwesomeWealthAwesome
$3.36 (52.50%)
120 day period
$6.10$8.09$10.07Feb 17May 13Aug 7

Advertisement

Market cap

$958.74M

P/E

162.7x

52W high

$10.17

52W low

$5.66

1W change

-0.81%

Beta

0.05

Analyst Price Targets

Based on analyst covering GUD

📈

Wall Street analysts forecast GUD stock price to rise 4.7% over the next 12 months.

Consensus

Neutral

Based on avg. target vs last close (formal rating unavailable for Canadian listings)

Avg. Target

C$10.21

+4.7% Upside

Current Price

C$9.76

Last close

Compare analyst targets across the TSX & TSXV →

Analyst ratings and price targets are updated periodically. Not financial advice.

Advertisement

Wealth Awesome Price Forecast

WA Model

Statistical 90-day price range based on GUD's historical volatility

HistoricalForecast68%95%
C$7.16C$9.00C$10.83C$12.67C$14.51C$16.34TodayMar 31Jun 4Aug 7Sep 19Nov 2Dec 15

30-Day Vol

25.7%

Annualized

90-Day Vol

30.5%

Annualized

Trend (90d)

+50.0%

Annualized drift

90d Mean

C$11.67

Expected price

HorizonExpected68% Range (1σ)
30 trading daysC$10.36C$9.48C$11.32
60 trading daysC$10.99C$9.70C$12.46
90 trading daysC$11.67C$10.01C$13.61

Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.

Analyst coverage: 1 analyst(s) cover this name; upcoming EPS consensus is available.

Beat estimates in 2 of the last 4 comparable quarter(s).

Fiscal periodReport dateActual EPSEstimateSurprise
2026-06-302026-08-06-0.02640.0300-188.0%
2026-03-312026-05-060.13890.0100+1289.0%
2025-12-312026-03-190.10000.0100+900.0%
2025-09-302025-11-06-0.01000.0200-150.0%
2025-06-302025-08-07-0.09000.0200-550.0%
2025-03-312025-05-080.0300-0.0100+400.0%
-0.09000.02440.1389 24-0924-1225-0325-0625-0925-1226-0326-06 Estimate Actual (≥0) Actual (<0) Wealth Awesome

Advertisement

Knight Therapeutics Inc. (TSX: GUD) reported its Q2 2026 earnings on August 6, 2026, and the results were disappointing, with an earnings per share (EPS) of -0.0264, missing the consensus estimate of 0.03 by a staggering 188.0%. This marks a notable deviation in performance, especially following two consecutive quarters of positive surprises.

Investor takeaway: The substantial earnings miss could impact investor sentiment and raise concerns over Knight's operational efficiency and future growth prospects. Investors should keep an eye on upcoming analyst revisions and market responses as the company navigates this setback.

EPS Miss of 188% Raises Red Flags

Knight's EPS of -0.0264 starkly contrasts with the expected 0.03, highlighting operational difficulties and potential market challenges ahead.

Bull case

Knight has shown it can bounce back, with two of the last four quarters delivering significant positive surprises. The company is focusing on strategic acquisitions and licensing, which could strengthen its product lineup and boost future revenue growth.

Bear case

The recent earnings miss raises concerns about the company's operational challenges and market positioning. With a low profit margin of 2.72% and a high P/E ratio of 162.67, there are signs of overvaluation. Continued earnings misses could lead to a decline in investor confidence.

Advertisement

Advertisement

Wealth Awesome
Written by

Wealth Awesome

Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.

View Full Profile →

✅ Reviewed by Certified Financial Professionals

This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.

Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.

📊 Data AccuracyVerified sources
🇨🇦 Canadian FocusLocal expertise
🔍 Fact-CheckedEditorial review

⚠️ Professional Disclaimer

This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.

Published: August 10, 2026
Last Updated: August 10, 2026

Sponsored links

Advertisement